Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, University of California, San Diego

Conditions

ER+, HER2-, Metastatic Breast CancerHR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerMetastatic Invasive Breast CancerResistant Breast Cancer

Phase 2

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Not yet recruitingNCT07729046

University of California, San DiegoER+, HER2-, Metastatic Breast Cancer, Metastatic Invasive Breast Cancer, Resistant Breast Cancer

Start: 2027-07-01End: 2035-06-01Target: 150Updated: 2026-07-27

Unknown Phase

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

CompletedNCT02753686

Novartis PharmaceuticalsHR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Start: 2016-03-15End: 2022-12-01Updated: 2023-02-15

Related Papers

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

2025-01-231 citations

Abstract PO2-17-01: Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study

Cancer Research2024-05-02

Abstract P1-19-36: Exploratory analysis of TreatER+ight; a Canadian prospective real-world observational study in HR+ advanced breast cancer

Cancer Research2020-02-15

Abstract P6-18-34: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: <i>3rd interim analysis</i>

Cancer Research2019-02-151 citations

Abstract P3-15-02: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: <i>2nd interim analysis</i>

Cancer Research2018-02-151 citations

Treat ER<sup>+</sup>ight: Canadian prospective observational study in post-menopausal HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer women—First interim analysis (IA).

Journal of Clinical Oncology2017-05-201 citations